CatalYm highlights GDF-15 as main anti-PD-1 resistance factor
Data underlines the significance of the company’s anti-GDF-15 antibody candidate, visugromab
Read More
Tag: catalym
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
